Persistent Depressive Disorder Persistent Depressive Disorder MCQ 3

Question 1

A 45-year-old patient has been on an SSRI for PDD for 8 weeks with minimal improvement. What is the most appropriate next step?

Accepted Answer

Increase the SSRI to the maximum labeled dose or consider augmentation/switch

Answer

After an adequate trial (typically 6–8 weeks at therapeutic dose), the next step is dose optimization, augmentation, or switching to another agent.

Question 2

Which psychotherapy modality has the strongest evidence base specifically for Persistent Depressive Disorder?

Accepted Answer

Cognitive Behavioral Analysis System of Psychotherapy (CBASP)

Answer

CBASP was specifically developed for chronic depression and has the most robust evidence for PDD treatment.

Question 3

A patient with PDD also meets criteria for Social Anxiety Disorder. How does this comorbidity typically affect prognosis?

Accepted Answer

It worsens prognosis and may require integrated treatment

Answer

Comorbid anxiety disorders worsen the prognosis of PDD, reduce treatment response, and often require targeted integrated interventions.

Question 4

Which of the following cognitive patterns is most characteristic of patients with Persistent Depressive Disorder compared to episodic MDD?

Accepted Answer

Rigid, trait-like negative self-schemas that persist even during relative wellness

Answer

PDD patients typically exhibit stable, deeply entrenched negative self-schemas rather than episodic cognitive distortions.

Question 5

What is the estimated lifetime prevalence of Persistent Depressive Disorder in the United States?

Accepted Answer

Approximately 2–4%

Answer

Lifetime prevalence of PDD is estimated at approximately 2–4% in the US general population.

Persistent Depressive Disorder Practice Test